$GLAND 💉 Gland Pharma: High-Margin Injectable Export Powerhouse

$GLAND Gland Pharma is well positioned to benefit from rising global demand for injectable drugs, complex generics, and contract manufacturing opportunities. The company has a strong presence in the US and international markets, supported by USFDA-approved facilities and a diversified product portfolio. For FY25, revenue remained around ₹5,600+ crore while EBITDA margins stayed healthy near 28–30%, reflecting strong operational efficiency. Net profit remained above ₹1,500 crore with strong cash generation and a virtually debt-free balance sheet, providing financial stability and expansion capability. The company continues expanding into oncology injectables, complex formulations, and CDMO opportunities, which can support future growth. Recent product launches, capacity expansion, and improving demand in regulated markets may further strengthen earnings visibility. With strong return ratios, export-led growth, healthy margins, and robust balance sheet strength, Gland Pharma remains a quality long-term pharma play. However, investors should monitor US pricing pressure, regulatory risks, and margin volatility.